2020 Y90 Master Class

Thursday - Session 1

Thursday - Session 2

Friday - Session 1

Friday - Session 2

Commercial Support Acknowledgment

This activity is supported by an educational grant from Sirtex.

Jointly provided by The France Foundation and The Society of Interventional Oncology

france.png     sio.png

About Yttrium-90 (Y90):

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and affects millions worldwide. Patients with early stage disease are eligible for curative therapies including surgical resection or liver transplant although most patients are diagnosed with advanced disease.

Yttrium-90 (Y90) microspheres are used for radioembolization procedures for patients with unresectable hepatocellular carcinoma and has demonstrated organ sparing benefits, proven efficacy in very advanced stages of HCC and good long term outcomes. Currently, there are two approved available Y-90 devices for administration and numerous ongoing trials aimed at exploring the current and future utility of radioembolization in hepatic malignancies. Despite it’s efficacy, intra-arterial Y90 is an under-utilized therapy and education on appropriate use remains scarce. This activity is developed to educate clinicians on this important modality to treat hepatic malignancies.